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ABSTRACT
The cysteinyl leukotrienes (CysLTs), leukotriene C4(LTC4), leukotriene D4(LTD4 ) and leukotriene E4(LTE4 ) are
released in response to specific allergen in nasal secretions from patients with active allergic rhinitis . The
symptoms and inflammation of allergic rhinitis can be induced by inhalation of CysLTs. Inflammatory cells from
patients with allergic rhinitis express both the synthetic and signaling proteins for the CysLT pathway. CysLTs
activate cell migration, in particular eosinophils, endothelial or epithelial cell adhesion and release of cytokines
and other oxidative inflammatory mediators. Cytokines may also activate the release of CysLTs from eosino-
phils and other myeloid cells and also enhance the expression of the CysLT1 receptor creating an inflammatory
amplification cycle. Systemic CysLT1 receptor antagonists can reduce the inflammation and symptoms of both
allergic rhinitis and asthma.
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INTRODUCTION
Activation of the leukotriene synthetic pathway oc-
curs in inflammatory or allergic cells following stimu-
lation of intracellular calcium release by specific
plasma membrane activating molecules such as bac-
terial cell wall antigens on neutrophils or IgE on mast
cells.1,2 Calcium release induces the translocation of
five-lipoxygenase (5-LO) and cytosolic phospholipase
A2 to the nuclear membrane where arachidonic acid
is released and presented to 5-LO by five-
lipoxygenase-activating protein (FLAP).3 FLAP is one
of the membrane associated proteins of eicosanoid
and glutathione metabolism (MAPEG ) family of
which there are six members that are involved in
either detoxification or eicosanoid synthesis. It is pos-
sible that FLAP evolved from an early evolutionary
detoxification role to a specific cofactor for the pro-
duction of leukotriene A4(LTA4). In the presence of
FLAP, 5-LO efficiently catalyzes a two-step reaction to
produce LTA4 that can be converted by perinuclear-
bound LTC4 synthase to LTC4 or by cytosolic LTA4
hydrolase to leukotriene B4(LTB4).3 LTB4 is a direct
activator of neutrophils, monocytes and macrophages
via activation of the BLT1 and BLT2 high affinity G
protein-coupled receptors ( GPCRs ) . 4 LTC4 is ex-
ported from cells via the MRP anion pump and con-
verted in blood by γ-glutamyltransferase to LTD4 and
then by dipeptidase action to LTE4. LTC4, LTD4 and
LTE4 are collectively called the CysLTs and they are
the components of slow reacting substance of ana-
phylaxis (SRS-A) . The CysLTs act on monocytes ,
macrophages, eosinophils and mast cells and on lung
and intestinal smooth muscle cells via specific activa-
tion of the CysLT1 andor CysLT2 GPCRs.5-9 Several
cellular processes may be activated by CysLT recep-
tor stimulation but intracellular calcium release ap-
pears to the primary signaling pathway.9
The CysLT synthetic and signaling proteins are ex-
pressed on inflammatory cells, including mast cells,
eosinophils and monocytesmacrophages in nasal se-
cretions from patients with active allergic rhinitis and
in mucosa from patients undergoing turbinectomies
for obstructed nasal passages.10,11 The three commit-
ted proteins in CysLT synthesis, namely 5-LO, FLAP
and LTC4 synthase, are expressed on 40% of mast
cells , 70% of eosinophils and 70% of monocytes
macrophages in nasal secretions. 10 Both CysLT re-
ceptors are expressed at approximately the same ra-
tios as the synthetic proteins on these inflammatory
cells. The CysLT1 receptor and 5-LO and FLAP (but
not the CysLT2 receptor or LTC4 synthase) are ex-
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Fig. 1 Potential CysLT signaling pathways in inflammatory cels in alergic rhinitis. Reprinted with permis-
sion from Figueroa DJ et al. Expression of cysteinyl leukotriene synthetic and signaling proteins in inflam-
matory cels in active seasonal alergic rhinitis. Clin. Exp. Alergy 2003; 33: 1380-1388.
pressed on 40―60% of neutrophils recovered in nasal
secretions from patients suffering from active allergic
rhinitis.10 The latter finding was not expected since
previously negligible CysLT1 receptor expression had
been observed on peripheral blood neutrophils from
normal individuals.12 It is possible that CysLT1 recep-
tor expression is enhanced during trafficking from
the blood into the nasal passages of patients suffering
from allergic rhinitis.10 Since 80―90% of eosinophils in
nasal secretions expressed both CysLT1 and CysLT2
receptors it is possible that these receptors could
form heterodimers as well as homodimers or oli-
gomers, but none of these structures has been con-
firmed. The CysLT1 receptor is also present on neu-
trophils, eosinophils, mast cells and vascular cells ,
but not on epithelial cells or submucosal glands, in
nasal mucosa samples from congested patients re-
quiring turbinectomies.11 A cartoon of the expression
of the CysLT pathway proteins and potential interac-
tion of CysLTs with their receptors in allergic nasal
tissues is depicted in Figure 1.
In allergic subjects, CysLTs (but not LTB4 ) are
elevated following specific ragweed allergen chal-
lenge in a ragweed pollen dose-dependent fash-
ion.13-16 The elevations in CysLTs correlate tempo-
rally with the severity of the symptoms of allergic
rhinitis.15 Intranasal challenge with LTD4 results in
nasal secretions (rhinorrhea) peaking at 5 minutes af-
ter LTD4 challenge and returning to control levels
within 20 minutes.16 In addition, intranasal LTC4 chal-
lenge in 5 patients increased nasal airway resistance
in a dose-dependent fashion.13
The severity of nasal blockage in allergic rhinitis is
proportional to the nasal eosinophil concentration.17
Activated eosinophils produce high amounts of
CysLTs which can act in an autocrine or paracrine
manner to activate eosinophil chemotaxis, migration,
degranulation and adhesion to β2 integrins on endo-
thelial or epithelial cells.18-21 LTD4 promotes chemo-
taxis of eosinophils with the rank order of potency of
agonists that reflects a CysLT1 receptor activation
profile , namely LTD4 > LTC4 > LTE4. 18 LTD4 en-
hanced eosinophil-derived neurotoxin release in-
duced by IL-5.19 In addition, LTD4 up-regulates ex-
pression of adhesion molecules such as Mac-1 and
can enhance the survival of eosinophils in vitro to a
similar degree as treatment with GMCSF.20-22 CysLT1
receptor antagonists reverse the ability of CysLTs to
prolong eosinophil life in vitro.22
CysLT treatment can increase the expression of
TH2 inflammatory cytokines such as IL-4 and IL-5
from eosinophils and mast cells.23,24 In reverse, TH2
cytokines can increase CysLT synthesis and CysLT1
receptor expression creating a cycle of inflammatory
mediator amplification.25-27 IL-13 and IL-4 have been
shown to increase CysLT1 receptor expression in hu-
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man monocytes and macrophages.26 IL-13 increases
CysLT1 receptor expression in human fetal lung fibro-
blasts lung fibroblasts and IL-13 has a synergistic ef-
fect with LTC4 on eotaxin production from these
cells.27 This eotaxin production was blocked by the
CysLT1 receptor antagonists montelukast and pranlu-
kast.27 These CysLT1 receptor antagonists can also
inhibit IL-5 expression in ragweed and mite-
stimulated peripheral blood mononuclear cells . 28,29
Interestingly montelukast also inhibited the synthesis
of CysLTs in peripheral blood mononuclear cells sug-
gesting that antagonism of the receptor decreased
the number of CysLT producing cells.29
The CysLT-stimulated production of non TH2 cy-
tokines such as MIP-1β and TNF-a may be blocked
by treatment with CysLT1 receptor antagonists . 23
Other inflammatory markers such as NO have been
shown to be elevated by LTC4 treatment of human
polymorphonuclear leukocytes in vitro. 30 Both mon-
telukast and pranlukast have been shown to reduce
exhaled NO in asthmatics . 31,32 Superoxide radicals
have the potential to initiate oxidative damage in cells
and LTD4 has been shown to increase these unstable
oxidation products in human eosinophils in vitro. 33
The increase in superoxide radicals was blocked by
treatment with the CysLT1 receptor antagonist pran-
lukast.33
As described above CysLT1 receptor antagonists
block effects of CysLT activation of eosinophils, mast
cells and neutrophils. Pranlukast has been shown to
be effective in the prevention of LTD4-induced nasal
secretion, nasal airway resistance and nasal eosino-
phil infiltration in a guinea pig model of allergic rhini-
tis.34 Pranlukast has also been shown cause a signifi-
cant decrease in eosinophil infiltration and cytokine
production in human nasal mucosa of patients with
perennial allergic rhinitis.35
Montelukast at 10 mg once daily dosing has shown
efficacy against daytime and nighttime symptoms and
improved quality of life scores in multi-center , ran-
domized , double-blind , placebo-controlled seasonal
allergic rhinitis trials held in spring and fall.36-38 In the
spring trial montelukast was also shown to decrease
peripheral blood eosinophil counts indicating both
nasal and systemic anti-inflammatory effects in this
trial.37
The pathophysiology of rhinitis has many common
features with that of asthma and 20―50% of patients
with rhinitis also have asthma, whereas 80% or more
of patients with asthma have concomitant rhinitis.39
This has lead to the hypothesis that systemic drugs
such as CysLT1 receptor antagonists may treat both
upper and lower airway disease treating the inflam-
matory‘one airway’ symptoms for patients with both
asthma and allergic rhinitis . 40-43 Urinary LTE4 has
been regarded as an index of systemic CysLT synthe-
sis and severe nasal blockage was shown to be asso-
ciated with increased urinary LTE4 concentration in
patients with seasonal allergic rhinitis.44 It will be of
interest to measure both activated leukocyte CysLT
synthesis and urinary CysLT production from pa-
tients with both asthma and seasonal allergic rhinitis
during both active and inactive allergen seasons .
More sophisticated analysis of LT products or LT
pathway polymorphisms may allow us in the future to
better define the population who would benefit most
by systemic CysLT antagonism or inhibition.
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